Impact of 2 Resuscitation Sequences on Management of Simulated Pediatric Cardiac Arrest

NCT05474170 | Completed

• 1 other identifier: CPR-AHA/ERC
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 1

Brief Summary

The International Liaison Committee on Resuscitation regularly publishes a Consensus on Science with Treatment Recommendations but guidelines can nevertheless differ when knowledge gaps persist. In case of pediatric cardiac arrest, the American Heart Association recommends following the adult resuscitation sequence i.e., starting with chest compressions. Conversely, the European Resuscitation Council advocates the delivery of 5 initial rescue breaths before starting chest compressions. Carrying out a randomized trial in children in cardiac arrest to assess the impact of these strategies would prove particularly challenging and ethical concerns may prevent such a trial from being performed. This will be a superiority, cross-over randomized trial whose goal is to determine the impact of these 2 resuscitation sequences on alveolar ventilation in a pediatric model of cardiac arrest. While not definitive, its results could help fill part of the current knowledge gap.

Conditions

Cardiopulmonary Arrest; Pediatric ALL; Resuscitation

Outcome Measures

Primary Outcomes (1)

• Alveolar ventilation

  The alveolar ventilation will be determined by subtracting the dead space volume from each ventilation. According to the appropriate Best Guess formula, a 9-month old infant should weigh around 9 kg (0.5 x age in months + 4.5). Using the formula proposed by Numa and Newth, this corresponds to a dead space of around 25 ml.

  1 minute

Secondary Outcomes (7)

• The total number of ventilations

  1 minute

• The proportion of ventilations within, above and below the target volume

  1 minute

• The alveolar ventilation obtained without taking ventilation volumes over 70 ml into account

  1 minute

• The proportion of compressions of correct depth

  1 minute

• The proportion of chest compressions within, above and below the target rate.

  1 minute

Study Arms (2)

AHA --> ERC

EXPERIMENTAL

This group will first apply the AHA resuscitation sequence, then the ERC one

Other: AHA resuscitation sequence; Other: ERC resuscitation sequence

ERC --> AHA

ACTIVE COMPARATOR

This group will first apply the ERC resuscitation sequence, then the AHA one

Other: AHA resuscitation sequence; Other: ERC resuscitation sequence

Interventions

AHA resuscitation sequence OTHER

Starting the cardiopulmonary resuscitation by following the AHA guideline, meaning starting with 15 chest compressions, followed by 2 ventilations

AHA --> ERC; ERC --> AHA

ERC resuscitation sequence OTHER

Starting the cardiopulmonary resuscitation by following the ERC guideline, meaning starting with 5 initial ventilations, then alternating 15 chest compressions with 2 ventilations

AHA --> ERC; ERC --> AHA

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Being issued from one of the following profession: Emergency medical technicians (EMTs), paramedics, nurses and physicians

You may not qualify if:

• Being member of the study team

Sponsors & Collaborators

• Geneve TEAM Ambulances: lead
• Service de la protection et de la sécurité, Neuchâtel: collaborator
• École supérieure de soins ambulanciers, Genève: collaborator
• University Hospital, Geneva: collaborator

Study Sites (1)

Swiss Prehospital Research Day

Neuchâtel, Canton of Neuchâtel, 2000, Switzerland

Location

Related Publications (1)

• Suppan L, Jampen L, Siebert JN, Zund S, Stuby L, Ozainne F. Impact of Two Resuscitation Sequences on Alveolar Ventilation during the First Minute of Simulated Pediatric Cardiac Arrest: Randomized Cross-Over Trial. Healthcare (Basel). 2022 Dec 5;10(12):2451. doi: 10.3390/healthcare10122451.

  PMID: 36553975 BACKGROUND

Related Links

• Whole project website

MeSH Terms

Conditions

Heart Arrest; Precursor Cell Lymphoblastic Leukemia-Lymphoma

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases; Leukemia, Lymphoid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Laurent Suppan, MD

  University of Geneva Hospitals and Faculty of Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Masking Details: Data extraction will be fully automated and the statistician will not know the identity of the participants or the sequence they were allocated to.
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: July 18, 2022
• First Posted: July 26, 2022
• Study Start: September 1, 2022
• Primary Completion: September 1, 2022
• Study Completion: September 1, 2022
• Last Updated: November 12, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will share
• Time Frame: Data will be available after publication of the results
• Access Criteria: Publicly available

Locations

CH (1)